Researchers have identified a new digital biomarker that correlates with lifetime smoking exposure and may reveal a tipping point after which smoking-related lung damage becomes far more likely to be irreversible[i], according to research published in Scientific Reports.
The features were identified in a study conducted by respiratory intelligence company TidalSense which set out to identify whether capnography data could be used to quantify the impact of cumulative tobacco exposure in people with confirmed chronic obstructive pulmonary disease (COPD).
Smoking exposure is commonly measured in ‘pack years’ – a clinical metric that reflects how many cigarettes someone has smoked over time. One pack year equates to smoking 20 cigarettes per day for one year.
Capnography measures the concentration of carbon dioxide (CO2) in exhaled breath over time, generating a waveform that provides insight into airway function and lung damage. Researchers analysed features associated with lung damage within this waveform to determine whether they were associated with cumulative smoking exposure.
Key study details:
Commenting on the research, Ameera Patel, CEO of TidalSense said: “We have known for a while that capnography can help us resolve lung physiology better than some commonly-used traditional tools. Identifying a digital biomarker that demonstrates a dose-response relationship between exposure and disease in this way could help researchers better understand how lung damage develops over time. The delineation of exposure risk is an important step forward in respiratory research and could ultimately support better prevention and earlier intervention in smoking-related lung disease.”
While capnography provides valuable insights into respiratory health, its clinical diagnostic use has been limited by the performance of traditional capnometers. TidalSense has overcome these challenges with the development of N-Tidal, a hand-held medical device designed to enable accurate, routine measurement of CO2 concentration during relaxed breathing.[iv]
To evaluate the clinical value of this approach, the study also assessed conventional spirometry metrics such as FEV1/FVC and percent predicted FEV1. However, these measures did not demonstrate the same clear relationship with smoking exposure, suggesting that capnography may provide additional insight into smoking-related airway remodelling that is not captured by spirometry.
While this study was conducted only in people with a confirmed diagnosis of COPD, the findings provide a foundation for further research to explore whether similar patterns exist in the wider population of active and passive smokers. Future work may also determine whether the biomarker could help identify people at risk of developing COPD earlier, potentially informing screening strategies and smoking cessation interventions.

TidalSense aims to improve respiratory diagnostics by delivering new insights into lung function and developing more accessible tools for earlier disease detection.
* One pack year = 20 cigarettes a day for one year (e.g. 10 a day = 0.5 pack years; 60 a day = 3 pack years).
About TidalSense
TidalSense is a respiratory technology company changing the way respiratory medicine is practised. Founded in 2013 and headquartered in Cambridge, UK, the healthtech company builds AI-based diagnostic solutions for COPD and asthma. The solutions, which use patented sensor technology, are able to detect changes in the lungs to automatically and more accurately diagnose respiratory conditions, creating efficiencies in healthcare environments and delivering a better patient experience.
About COPD and smoking
References
[i] Lim, R.H., Talker, L., Broomfield, H. et al. Quantification of smoking-related airway remodelling in COPD, using N-Tidal. Sci Rep 16, 8713 (2026). Available at: https://doi.org/10.1038/s41598-026-41699-6.
[ii] Talker, L. et al. Diagnosis and severity assessment of COPD using a novel fast-response capnometer and interpretable machine learning. COPD: J. Chronic Obstr. Pulmonary Disease. 21 (1), 2321379 (2024).
[iii] Talker, L. et al. Machine diagnosis of chronic obstructive pulmonary disease using a novel fast-response capnometer. Respir Res. 24 (1), 1–11 (2023).
[iv] Bate, S.R. et al. N-Tidal C: A Portable, Hand Held Device for Assessing Respiratory Performance and Injury. American Journal of Respiratory and Critical Care Medicine . 197, A2371 (2018).
[v] Boers E, Barrett M, Su JG, Benjafield AV, Sinha S, Kaye L, Zar HJ, Vuong V, Tellez D, Gondalia R, Rice MB, Nunez CM, Wedzicha JA, Malhotra A. Global Burden of Chronic Obstructive Pulmonary Disease Through 2050. JAMA Netw Open. 2023 Dec 1;6(12):e2346598. Available at https://pmc.ncbi.nlm.nih.gov/articles/PMC10704283
[vi] World Health Organization. Chronic obstructive pulmonary disease. 7 March 2024. Available at: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)
[vii] Jayes, L. et al. SmokeHaz: Systematic Reviews and Meta-analyses of the Effects of Smoking on Respiratory Health. Chest. 150(1), 164-79 (2016).
[viii] Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019) Reference Life Table. Seattle, United States of America: Institute for Health Metrics and Evaluation (IHME). https://doi.org/10.6069/1D4Y-YQ37 (2021).
[ix] Goodchild, M., Nargis, N. & Tursan d’Espaignet E. Global economic cost of smoking-attributable diseases. Tobacco Control. 27, 58-64 (2018).